Barclays’s Liminatus Pharma LIMN Stock Holding History

Barclays’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-86	Closed	-$474	–	5831
2026 Q2	$474	Buy	+86	New	+$743	﹤0.01%	5014
2025 Q3	–	Sell	-4	Closed	-$2.05K	–	5788
2025 Q2	$2.05K	Buy	+4	New	+$2.24K	﹤0.01%	5037

Barclays's LIMN Position: Q3 2026 in Review

Barclays sold out of Liminatus Pharma (LIMN) in Q3 2026, closing a stake of 86 shares — an estimated $474 sold.

Barclays first reported a position in LIMN in Q2 2025 and held it in 2 quarters. The position peaked at $2.05K in Q2 2025. 0 funds tracked by Wall St. Rank hold LIMN as of Q3 2026.

Barclays reported no remaining Liminatus Pharma position as of Q3 2026 after selling out during the quarter.
Barclays sold 86 Liminatus Pharma shares in Q3 2026, an estimated $474.
Barclays first reported a position in Liminatus Pharma in Q2 2025 and held it in 2 quarters.
Barclays's Liminatus Pharma position peaked at $2.05K in Q2 2025.
0 funds tracked by Wall St. Rank held Liminatus Pharma as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.